FDA Clears Adjunctive AI for Non-Contrast CT of Brain Injuries and Hemorrhages
RapidAI’s Rapid Hyperdensity tool reportedly allows quicker assessment of hyperdense tissue in the brain via non-contrast computed tomography (CT) scans.
RapidAI has received FDA 510(k) clearance for Rapid Hyperdensity, an artificial intelligence (AI)-enabled tool that may allow for more timely assessment of traumatic brain injuries and hemorrhages.
Rapid Hyperdensity’s AI-powered review of non-contrast computed tomography (CT) enables radiologists to quickly determine the extent of hyperdense tissue volume associated with acute neurological conditions such as intracerebral hemorrhage (ICH), according to RapidAI.
Alejandro M. Spiotta, M.D., said the automated detection of intracranial hyperdense tissue volume with Rapid Hyperdensity is a significant advance in facilitating timely triage and ongoing assessment of patients with ICH.
“Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient,” noted Dr. Spiotta, the director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
